July 01, 2025

FDA Approves Low-IgA IG Therapy

GAMMAGARD LIQUID ERC is the first ready-to-use liquid immunoglobulin therapy with IgA ≤2 µg/mL for primary immunodeficiency in individuals aged 2 years and older.

Conexiant

June 30, 2025

Can Typos Change a Diagnosis?

Large language models used in clinical decision-making may offer different treatment recommendations depending on how a patient writes their message—even when the medical facts remain unchanged.

Conexiant

June 24, 2025

Dermatologists Show Lowest Turnover Intent of All Specialists

AMA data show only 19.9% of dermatologists plan to leave their current positions, compared with 40.6% of anesthesiologists.

Conexiant

June 23, 2025

What’s the Dose for Hair Regrowth?

A national survey found wide variation in intralesional corticosteroid injection techniques among US hair specialists treating different types of alopecia.

Conexiant

June 23, 2025

Remote and Ready: Rethinking COPD Care

A large meta-analysis of 33 trials found that community-based COPD management models improved lung function, exercise capacity, and symptom control compared to usual care, though quality-of-life gains were not significant.

Conexiant

June 09, 2025

New Fixed-Dose RSV Antibody Approved

The FDA has approved enflonsia, a fixed-dose monoclonal antibody, for preventing RSV lower respiratory tract disease in infants during their first season.

Conexiant

June 06, 2025

RSV or COVID: Which Strains the Heart?

A study of 32,960 hospitalizations finds 10.9% of patients with RSV experienced acute cardiovascular events, with significantly higher adjusted odds than boosted and unboosted COVID-19 cases.

Conexiant

June 04, 2025

Big Tobacco's Medical Research Infiltrates Journals

Investigation reveals tobacco-funded studies appear in top medical journals despite industry bans, as companies invest billions in pharmaceutical subsidiaries.

Conexiant

June 04, 2025

Dog Exposure May Lower Genetic Eczema Risk

A large European study found that early-life dog exposure may reduce the genetic risk for atopic eczema, with lab results confirming a biological mechanism involving immune signaling in skin cells.

Conexiant